key: cord-0046667-dzd009zg
authors: Shi, Wei; Jin, Weiwei; Xia, Linghui; Yu, Hu
title: Novel agents targeting leukemia cells and immune microenvironment for prevention and treatment of relapse of acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation
date: 2020-06-30
journal: Acta Pharm Sin B
DOI: 10.1016/j.apsb.2020.06.012
sha: 2963c475a284a21bcfb13f88f210cf3c097e2819
doc_id: 46667
cord_uid: dzd009zg

Relapse remains the worst life-threatening complications after allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with acute myeloid leukemia (AML), whose prognosis has been historically dismal. Given the rapid development of genomics and immunotherapies, the interference strategies for AML recurrence have been changing these years. More and more novel targeting agents that have received the U.S. Food and Drug Administration (FDA) approval for de novo AML treatment have been administrated in the salvage or maintenance therapy of post-HSCT relapse. Targeted strategies that regulate the immune microenvironment of and optimize the graft versus leukemia (GVL) effect of immune cells are gradually improved. Such agents not only have been proven to achieve clinical benefits from a single drug, but if combined with classic therapies, can significantly improve the poor prognosis of AML patients who relapse after allo-HSCT. This review will focus on currently available and promising upcoming agents and also discuss the challenges and limitations of targeted therapies in the allogeneic hematopoietic stem cell transplantation community.

hedgehog signaling pathway inhibitors. Secondly, novel agents disrupt key metabolism of leukemia cells without directly damaging DNA. Examples include DNA hypomethylating agents and histone deacetylases inhibitors. A final group consists of leukemia epitope-targeting agents. Such immunotherapeutic strategies include antibody conjugate cytotoxic agents and antibody-based cellular therapies.

Most agents will be formally introduced in the review. 19 . Such mutations have been reported in approximately one third of patients with AML and are associated with higher relapse rates 21 . Sorafenib, midostaurin, quizartinib, gliteritinib and crenolanib are designed to target FLT3 and have been used to interfere with the relapse of FLT3 positive AML after allo-HSCT.

Sorafenib has been used to treat relapsed FLT3-ITD positive AML following allo-HSCT. In a large registered study, 409 relapsed FLT3-ITD positive patients after allo-HSCT were analyzed. There were five arms in the study. The complete remission (CR) and 1-year OS of DLI arm were 22% and 17%, respectively, which increased to 67% and 47% when used in combination with sorafenib 22 . The studies from European Society for Bone Marrow Transplantation (EBMT) and China showed similar results that sorafenib combined with DLI obviously improved the OS and leukemia free survival (LFS) of relapsed FLT3-ITD positive patients following allo-HSCT 23, 24 . As a preventive or maintenance medication after allo-HSCT, sorafenib decreased the 3-year incidence of relapse (CIR) of FLT3-ITD positive patients from more than 50% to 15% in a series of retrospective studies [24] [25] [26] [27] [28] [29] [30] . For the safety of sorafenib as a prophylactic agent, a prospective study depicted that the 3-year OS was 76% and the most common 3/4 adverse events were hepatic enzymes (23%) and thrombocytopenia (17%) 31 . In a randomized phase 3 trial, the other first generation FLT3 inhibitor, midostaurin or placebo, was used for 717 patients from induction therapy to maintenance therapy due to their capability of targeting both TKD and ITD mutations, and 57% of the patients discontinued the trial therapy because of allo-HSCT. Although patients who achieved CR1 and received allo-HSCT in both groups did not reach the median OS, the OS in the midostaurin group was significantly longer than that in the placebo group, at 69.8 and 21.8 months, respectively 32 . After that, as a prophylactic agent in a phase 2 hypothesis-generating trial, midostaurin controlled the post-HSCT 2-year CIR of FLT3 positive patients to 13.3% 33 .

As the next generation FLT3 inhibitors, quizartinib, gliteritinib and crenolanib were more targeted than the first generation, and thereby off-target-associated toxicities and side effects were decreased. Quizartinib demonstrated acceptable tolerability for de novo or post-HSCT AML patients in the phase1 dose escalation studies, and the most common grade 3/4 adverse events were neutropenia, thrombocytopenia, and anemia 34, 35 . For patients with relapsed/refractory (R/R) FLT3-ITD positive AML, the rate of quizartinib monotherapy bridging allo-HSCT reached 32%, which was significantly higher than 11% of salvage chemotherapy 36 , especially in the 60 mg/day group 37 . For R/R FLT3-mutated patients, another inhibitor, gilteritinib, had an overall response rate (ORR) of 80% in the phase 1 clinical trial and was well tolerated 38 . In a phase 3 trial, 371 R/R FLT3-mutated patients were randomly assigned in a 2:1 ratio to receive either gliteritinib (at a dose of 120 mg/day) or salvage chemotherapy. Gilteritinib resulted in significantly longer LFS (2.8 vs. 0.7 months) and higher CR percentage (21% vs. 10.5%) than salvage chemotherapy 39 .

As a potent typeI pan-FLT3 inhibitor, crenolanib retains the activity against FLT3-TKD mutation, which is a candidate for patients resistant to the other FLT3 inhibitors. Cumulatively, a high ORR (28%) was achieved with crenolanib monotherapy for such patients 40, 41 . Since the phase 2/3 clinical trials of the next generation FLT3 inhibitors for maintenance therapy after allo-HSCT are being recruited, and none of them use a first-generation inhibitor as a control, so it is impossible to determine whether they are superior to the first-generation agents.

BCL-2 is an anti-apoptotic protein which binds to the BH3 and inhibits the apoptosis of hematologic malignancies. As a BCL-2 inhibitor, venetoclax competitively binds to the BH3 domain of BCL2, releases BH3-only proteins and induces apoptosis 42 . A phase 2 study demonstrated that venetoclax monotherapy for R/R AML or unfit for intensive chemotherapy patients achieved an ORR of 19% with an acceptable safety profile 43 . Currently, venetoclax has being investigated in a series of phase 1 studies in combination with low-dose cytarabine and decitabine or azacitidine 44 . For older de novo AML patients (median 75 years), venetoclax in combination with azacytidine achieved the CR/CRi rate up to 85%, compared with the 51% for conventional therapy (P=0.0019) 45 . Such two-drug combination treatments reduced succinate dehydrogenase glutathionylation, impaired the tricarboxylic acid cycle, and depleted ATP in leukemia stem cells 46 . In addition, only a few patients who relapse after allo-HSCT have achieved CR after combination therapy with venetoclax and low-dose cytarabine or DNA hypomethylating agents 47, 48 . Currently, there are two initiated prospective studies to evaluate the efficacy of venetoclax in combination with azacitidine to improve relapse free survival (RFS) in AML patients when given as maintenance or preemptive therapy following allo-HSCT. For patients presenting WBC above 25 G, uric acid above 7.5 mg/dL, or creatinine above 124 mmol/L, physicians need to know that the initiation of venetoclax-based therapy may elevate the risk of tumor lysis syndrome (TLS) 49 .

Somatic mutations within the conserved active site of isocitrate dehydrogenases (IDH) 1 and 2 occur in 6%-10% and 8% -19% of patients with AML, respectively.

These mutations cause accumulation of the oncogenic metabolite R-2-hydroxyglutarate (2-HG), 2-HG competitively inhibits α-ketoglutaratedependent enzymes, leading to DNA and histone hypermethylation and impairing hematopoietic differentiation 50, 51 . Ivosidenib and enasidenib are oral targeted IDH1 and IDH2 inhibitors, respectively 52 . In a phase 1 study of IDH1-mutated R/R AML, administration ivosidenib at a dose of 500 mg daily achieved durable CR (21.6%, 9.3 months) and ORR (41.6%, 6.5 months) with a low frequency of grade 3 or higher adverse events 52 . For IDH2 mutation R/R AML patients, enasidenib was well tolerated and produced an ORR of 40 % in a phase 1 trial 50, 53 . Almost 20% patients attained CR, 43.1% red blood cell and 40.2% platelet transfusion-dependent patients achieved transfusion independence 51 . In addition, isocitrate dehydrogenase differentiation syndrome (IDH-DS) is a potentially lethal and recognizable complication. In a retrospective study of IDH-DS in 281 R/R AML patients, researchers recognized that approximately 12% of the patients were identified as IDH-DS, prompt diagnosis and systemic administration corticosteroids were effective for them 54 .

The Hedgehog (Hh) signaling pathway should be silenced in adults 19 , however, overexpression of Hh pathway components is observed in myeloid leukemia cells resistant to chemotherapy, especially in leukemia stem cells 55 . Aberrant Hh pathway releases transmembrane protein smoothened (SMO), which activates glioma (GLI)-associated proteins 56 . GLI is translocated into the nucleus and binds the promoter region of target DNA to express specific oncogenes, such as those encoding c-MYC, BCL2, and SNAIL 55 . Glasdegib is an oral small molecule inhibitor of SMO, which prevents SMO from translocating into the primary cilia 56 .

In a phase 1b study, glasdegib was administered once daily in 28-day cycles in combination with low-dose cytarabine (arm A), decitabine (arm B) or cytarabine/daunorubicin (arm C), and the recommendation dose for glasdegib was 100 mg/day 57 . The following phase 2 study showed that 46.4% of patients achieved CR, and the median OS was 14.9 months. The most common treatment-related adverse events (≥50% patients) were diarrhea and nausea 56 . In a randomized phase 2 trial of AML or high-risk myelodysplastic syndrome (MDS) unsuitable for intensive chemotherapy, patients were randomized (2:1) to glasdegib (100 mg/day) and low dose cytarabine (LDAC) or LDAC (20mg, Bid) only arms. The CR rate and median OS of the two arms were 17% vs. 2.3% (P<0.05) and 8.8 months versus 4.9 months (P=0.0004), respectively 58 . In a randomized phase 3 clinical trial, the efficacy of glasdegib maintenance vs. clinical observation after allo-HSCT will be evaluated until December 2026.

HMA not only leads to hypomethylation of the promoter of silenced tumor suppressor genes, but also has the ability to enhance antigenicity and regulate immune checkpoints, and can induce CD8 + T cells to respond to tumor antigen after transplantation, thereby increasing GVL response without increasing the risk of graft versus host disease (GVHD) [59] [60] [61] . Azacytidine (AZA) and decitabine (DEC) are not really novel agents, but as the representative of HMA, clinicians have been very enthusiastic about their application in recurrence patients after allo-HSCT. In a series of retrospective studies, salvage therapies with AZA or DEC for morphological recurrence rescued very limited patients. Even with DLI booster immunotherapy, only 3%−27% of patients achieved CR, and the 2-year OS was between 11% and 29% [60] [61] [62] [63] [64] [65] . In order to enhance the antitumor efficacy of HMA, 29 relapsed patients post-HSCT were treated with sequential AZA (75 mg/m 2 , 7 days) followed by escalating doses of LEN from Day 10 to 30 in the VIOLA trial. Almost 47% of patients achieved a major clinical response and 40% achieved a CR/CRi after LEN/AZA therapy 66 . Because HMA was safe for long-term use, AZA monotherapy was given as an MRD-guided preventive treatment in a phase 2 trial to prevent morphological recurrence. A total of 198 patients were screened in the study, 60 of whom developed MRD (CD34 + cell donor chimerism<80%, fusion or mutant gene>1%) during the 24-month screening period, and 53 of them were treated. Six months after initiating AZA treatment, 58% of patients were free of relapse and alive, while 75% of patients survived more than 12 months 67 . For initiating CD8 + T cell response to tumor antigens, AZA maintenance therapy in high-risk AML patients after allo-HSCT was well tolerated and has the capacity to reduce the relapse risk 68, 69 .

In a series of preventive treatments, low dose AZA in combination with DLI reduced the CIR of high-risk patients without increasing the cumulative incidence of GVHD 70 . CC-486 is an oral AZA, which can be used more conveniently. In a prospective phase 1/2 dose-finding study, CC-486 maintenance therapy for high-risk AML patients post-HSCT was generally well tolerated with low relapse rates (21%) and low GVHD (10%) 71 . Although the double-blind, phase 3, randomized study of CC-486 has just been initiated on June 14, 2019, for patients who need long-term home medication after allo-HSCT, their compliance to it will be better than traditional AZA and more likely to benefit from it.

Myeloid oncoproteins aberrantly recruit histone deacetylases (HDAC), causing chromatin remodeling and inhibiting the expression of tumor suppressor genes such as TP53 72 . Panobinostat (PAN) is a potent oral HDACi, which can modulate the acetylation of histone proteins and protein chaperones in malignant cells 73 . In the phase 1/2 PANOBEST trial, PAN was prophylactically administrated after allo-HSCT for AML or MDS. At 2 years after the first PAN dose, the cumulative incidence of relapse, non-relapse mortality and OS across all dose levels was 20%, 5% and 81%, respectively. About 52% of patients experienced reversible PAN-related G3/4 adverse events and 29% of patients experienced GVHD 74 . PAN (30mg)+AZA (75mg/m 2 ) or AZA monotherapy was administered to high-risk MDS, CMML or AML with low burden (<30%) blasts in a phase 1b/2b trial. Although patients in PAN+AZA arm achieved better CR/CRi (27.5% vs. 14.3%), which resulted in more grade 3/4 adverse events (97.4% vs. 81.0%) and treatment-related deaths (13.2% vs. 4 .8%) 73 . Lower dose PAN (20 mg) in combination with idarubicin and cytarabine (3+7) as inducing therapy for younger patients (median age, 55.5) with high-risk AML demonstrated tolerable toxicity and improved CR/CRi (60.9%) 75 . For older AML patients (median age, 69), the CR/CRi of PAN with "3+7" strategy was 32%, whichwas significantly associated with an increase in histone acetylation in peripheral blood mononuclear cells (PBMCs) after treatment 76 . In March 2020, a randomized multicenter phase 3 study was initiated to assess the efficacy of PAN 20 mg oral three times weekly every second week vs. standard of care following allo-HSCT. Since February 2019, another HDACi (vorinastat) combined with low-dose AZA as post-HSCT maintenance treatment has been studied in a phase 1 dose-escalation clinical trial, and the results will be announced after December 2021. 

Antibody conjugate cytotoxic agents provide a method for delivering cytotoxic agents to leukemia cells, thereby increasing dose intensity while reducing toxicity 83 . [90] [91] [92] [93] . In a small sample study, cytarabine and GO (9 mg/m 2 ) were used as post-HSCT salvage therapy for AML patients, but only 25% of patients survived more than one year and all relapsed 94 . In a study of CD33-positive leukemia children receiving reduced-intensity conditioning (RIC) transplantation and using CD33 as maintenance therapy, patients were given two doses of GO (8 weeks apart) in a dose-escalation design (4.5, 6, 7.5, and 9 mg/m 2 ) 6 days after allo-HSCT. The 1-and 5-year OS probabilities were 78% and 61%, respectively, and no toxicity that might be directly or directly related to GO was observed 95 . The data of phase 1 clinical trial for the preventive use of GO by patients receiving RIC allo-HSCT will be released as early as December 2020.

Vadastuximab talirine (SGN-CD33A, 33A) is an antibody−drug conjugate consisting of pyrrolobenzodiazepine dimers and an anti-CD33 monoclonal antibody.

In a phase 1 clinical trial, 33A monotherapy was infused to CD33-positive AML patients at a dose of 40 mg/kg, and 28% of them achieved CR/CRi, of which 14% were MRD-negative 96 . In an expansion arm of this study, 33A subsequently in combination with HMAs were provided to de novo CD33-positive older AML patients (median 75 years), and 70% of them achieved CR/CRi, of whom 51% were MRD-negative. In addition, the 30-and 60-day mortality rates were 2% and 8%, respectively 97 . In the terminated phase 1/2 trial (Table 1) , 33A was used as maintenance therapy after allo-HSCT. Unpublished data showed that the most common adverse events were neutropenia and thrombocytopenia.

WT1 is a non-polymorphic intracellular protein that promotes proliferation and carcinogenesis in AML, and is overexpressed 10−1000 times in leukemia cells compared to normal CD34 positive cells 98, 99 . In a phase 1 pilot study, WT1-directed peptide vaccination was injected subcutaneously to 16 heavily pretreated AML and MDS patients, which exhibited a protective immune response (IR) and was well tolerated 98 . In a phase 2 study, injection of the WT1 peptide vaccine stimulated a specific IR in patients with AML and was associated with the survival in excess of 5 years 100 . After dendritic cells (DCs) were electroporated with WT1 mRNA and injected as a vaccine into AML patients with CR1, they induced the response of WT1-specific CD8 + T, reduced the relapse rate by 25%, and were well tolerated 101 .

In a small pilot study, HLA-A2 positive recipients were vaccinated with a WT1 peptide-loaded donor-derived DC vaccine every two weeks and given a DLI every four weeks to increase specific GVL effect, which was well tolerated and no grade 3 or higher adverse events directly related to the vaccine were found 102 . Because WT1-specific (HLA-A* 24: 02) TCR-T cells can survive in vivo and retain a specific immune response to WT1 103 , Chapuis et al 99 . isolated a high-affinity WT1-specific TCR (TCR C4 ) and inserted it into EBV-specific donor CD8 + T cells to make the T TCR-C4 cells. Twelve high-risk patients after allo-HSCT received at least one preventive infusion of TCR C4 (total 21 infusions). Compared with 88 patients in a concurrent comparative group, the median 44-month RFS was 100% vs. 54% without increasing the risk of chronic GVHD. However, the data as salvage or preemptive treatment have not yet been released.

CXCR4 is a key player of AML blasts, which binds with CXCL12 for retention of leukemia cells in the protective bone marrow (BM) microenvironment 104, 105 . The Leukemia stem cells always employ CXCL12/CXCR4 to home toward the protective marrow niches 106 . In a phase 1 study, one dose plerixafor was injected to 12 patients before the first dose of fludarabine and busulfan to make sure more leukemic stem cells deletion before allo-HSCT. The engraftment rate was 100%, the median OS was 67 months, and only 2 patients (17%) relapsed 108 .

CAR T cell therapy has gained 90% of response rates in CD19 + ALL and CLL, which combines a monoclonal antibody of tumor epitope to intracellular T-cell receptor signaling domain by taking advantage of a single-chain variable fragment (scFv). Because of the greater heterogeneity of AML, one of the major challenges in translating the amazing clinical success of CAR T cells in ALL into AML is to find suitable leukemia cell surface markers 109 . Over the past five years, studies have been changing from using traditional AML antigens (such as CD33, CD123, CD44, TIM-3 or CD13) to using normal hematopoietic stem cells that do not express, while leukemia cells or leukemia stem cells overexpress antigens (e.g., folate receptor β, CLL-1, NKG2D, CD7 or FLT3) to reduce the off-target toxicities [109] [110] [111] [112] [113] [114] [115] . The efficacy of CAR T cells is often related to its durability in vivo. Zheng et al. 116 and demonstrated that they can be implanted and differentiated normally in immunodeficient mice and rhesus monkeys 119, 120 . CD33-ablated HSPC were impervious to CD33-targeted immunotherapy (CAR T or GO), allowing for efficient elimination of CD33 positive blasts without myelotoxicity, which provided new ideas for the application of CD33-targeted immunotherapy in combination with auto/allo HSCT.

With the recognition of immune-escaping driving to two-thirds of relapse post-HSCT, it seems valuable to rapidly translate it into personalized medication. For example, second transplantation from different donor for patients with genomic HLA loss 1, 121, 122 , CPIs for patients with upregulation of IRs and inducing moderate chronic GVHD for those with downregulation of HLA class II genes [10] [11] [12] . However, in clinical practice, this translation will be subject to many restrictions, for example, alternative donor unavailable and relapse with active GVHD, etc. DLI is still an attractive treatment option for patients with high risks of recurrence or recurrence.

Unfortunately, approximately 31.6%−66% of recipients obtained II−IV acute GVHD after DLI [123] [124] [125] [126] , 50% obtained chronic GVHD, and 26% of patients eventually died of GVHD related complications 127, 128 . Using engineered donor T cells or NK cells to improve GVL effect and reduce GVHD is a promising strategy that is currently being extensively studied 129 . In addition, this review will describe strategies for activating endogenous IL-15 expression in the immune microenvironment to improve the GVL effect of immune cells and avoid systemic toxicity 130 .

CTLA-4 and PD-1 are the well-known immune checkpoints for tumor immune escape 131 . CTLA-4 and PD-1 interact with ligands B7-1/B7-2 and PD-L1/PD-L2, respectively, and can inhibit the complete activation and proliferation of T cells 132, 133 .

Recently, monoclonal antibodies directed against immune checkpoints have benefited some patients who have relapsed after allo-HSCT. In the dose-escalation study, human anti-CTLA4 monoclonal-ipilimumab was infused in 29 patients (2 AML) who had relapsed more than 90 days after allo-HSCT or DLI. Ipilimumab did not result in clinically significant GVHD, and a response was observed in three lymphoma patients 134 . In the following phase 1/1b study, of the 22 patients receiving the 10 mg/kg dose, 23% had a complete response, including 4 patients with extramedullary AML and 1 patient with secondary AML. Because of GVHD, 4 patients had to discontinue further use of ipilimumab 133 . In a small sample study, the anti-PD1 antibody−nivolumab was given to 3 AML patients who had relapsed after allo-HSCT and failed standard therapies. One patient achieved an ongoing CR, one patient experienced disease stabilization and the side effects were tolerable 135 . In a review of 28 papers comprising 176 patients using CPIs (ipilimumab or nivolumab) after allo-HSCT, the ORR was 54% (CR 33%, PR 21%), 23% of patients developed GVHD and 28% of mortality was GVHD related 132 . However, Christopher et al. 10 reported that the expression of PD1 on T cells was undetectable in 15 AML patients who had relapsed after allo-HSCT. Therefore, it will be valuable to determine the prevalence of immune checkpoints expression to predict whether these patients will respond to CPIs.

DLI is one of the standard treatments for recurrence after allo-HSCT. It can play a GVL effect by identifying minor histocompatibility antigens and leukemia antigens.

However, the long-term efficacy of DLI in AML patients who had relapsed after allo-HSCT was only 15%−29%, and most of them were accompanied by significant GVHD 136 . More and more studies have been using engineering DLI to improve GVL effect and reduce GVHD. In a phase 1 study, CD25 + regulatory T cells were depleted from donor lymphocytes to avoid their inhibition of GVL effect. Compared to unmodified DLI, T reg depletion was associated with better response rate (62.5% vs.

28.6%) and improved event-free survival (27% vs. 0%) without excessive GVHD 136 .

CD8 + CD44hi memory T cells may have a more specific GVL effect, which were isolated and purified and given to fifteen patients in a phase 1 study. Ten patients achieved response (7 CR, 1 PR, 2 SD) for at least 3 months after infusion, and the incidence of GVHD was low 137 . CD200 is usually high expressed on leukemia cells, which binds to CD200 receptor on T-cell and negatively regulates T-cell function.

Scientists used the costimulatory receptor-CD28 to replace the cytoplasmic tail of CD200R immunomodulatory fusion protein (IFP), and transduced the CD200R-CD28 IFP to CD8 T cells. It can eradicate blasts more efficiently than wild-type cells, and does not require interleukin 2 to maintain in vivo activity 138 .

Donor NK cells treatment is the other arm to control blasts escaping. In a phase 2 study, haploidentical NK cells were successfully isolated and infused to AML patients who had relapsed following allo-HSCT. Patients with higher expression of KIR2DL2/2DL3/2DS2 at 14 days after haploidentical NK cell infusion achieved better survival 139 . Especially, allografts from donors who were positive for KIR2DS1 had more powerful anti-leukemia effect than negative. Donor KIR3DS1 was associated with reduced mortality 16, 17 . In a phase 4 study, 84 AML patients with CR1 received histamine dihydrochloride and low-dose IL-2 for 18 months or until relapse/death. Patients carrying HLA-21M harbored better educated NKG2A+cells and displayed superior capacity to degranulate lytic granules against KIR ligand matched blasts 140 . A series of clinical trials using engineered NK cells, such as invariant NKT cells or cytokine-induced memory-like (CIML) NK cells, will provide more and more options for the preventive and salvage therapy of recurrence after allo-HSCT.

IL-15 is a λc-chain cytokine with unique properties to stimulate antitumor immunity, including stimulation of NK cells and CD8 + memory T cells 141 . In a mouse model of relapse after allo-HSCT, systemic IL-15 infusion often increases GVL activity with severe GVHD 22 . Therefore, strategies are focused on activating endogenous IL-15 expression to avoid the toxicity from a systemic administration. In a large registered study, the FLT3 inhibitor-sorafenib was used to treat relapsed FLT3-ITD positive AML patients after allo-HSCT, which can indirectly activate the IL-15 transcription and induce the leukemia cells to produce IL-15. Thus, a strong GVL effect was promoted without inducing obvious GVHD 22 . Compared to the cytotoxic chemotherapy arm, sorafenib obviously improved the CR (18.5% vs. 32.5%) and

1-year OS (10.5% vs. 22%) of patients. AML blasts always lack expression of the costimulatory molecule CD80. In a preclinical study, 32Dp210 murine AML cells were engineered to express heterodimeric IL-15/IL-15Ra together with CD80 and tested as irradiated cell vaccines, which markedly increased IL-15 stability and secretion. Compared to the 100% relapse and death of control group, the OS of vaccination group was 50% 141 . In a multicenter phase 1 trial, IL-15 superagonist complex ALT-803 was administered to 33 patients who relapsed >60 days after allo-HSCT. ALT-803 was well tolerated and stimulated the activation, proliferation and expansion T cells without increasing T reg cells. Responses were observed in 19% of evaluable patients, including 1 patient who achieved a CR for 7 months 142 .

Once recurrence after allo-HSCT happens, patients and physicians have to face the problem of making a choice to change the dismal prognosis. Leukemia cells always acquire new oncogenic mutations, and patients may not tolerate or become resistant to conventional cytotoxicity chemotherapy 11, 143 . Unavailable donor, HLA loss or active GVHD are always greatly limiting the application and the efficacy of traditional DLI and second transplantation 10, 11, 121, 144 . Compared with traditional treatments after allo-HSCT, the novel agents have a good response, well tolerance and low toxicity, which are summarized in Fig. 1 . However, scientists and clinicians need to discover new approaches to prevent and treat recurrence after allo-HSCT according to the following rules. First, we must discard the notion that donor cell booster therapy is the only definitive therapy and pay more attention to the development of targeted drugs for AML. For example, we should focus on the epigenetic therapeutic targets currently being evaluated in AML: the MLL rearrangements 145, 146 , the lysine demethylase LSD1 147 , the protein methyltransferases EZH2, DOT1L 148 , and PRMT5 149, 150 , and the BET bromodomain proteins 146, [151] [152] [153] [154] [155] . Second, if safety and effectiveness are shown, it is best to use these drugs in advance in a preventive or preemptive manner, rather than just "watch and wait" for the miraculous GVL effect until the disease recurs. For example, the 3-year OS of sorafenib for post-transplant prophylaxis is 76%−84.6%, compared to 50.9% for controls 22, 27, 156 . Unfortunately, clinical trials using novel agents as maintenance treatment after allo-HSCT are scarce, and many uses are based on the off-protocol access. The clinical trials using novel agents are summarized in Table 1 . Third, a suitable synergistic strategy can achieve better therapeutic effects without generating additional toxicity, such as coupling FLT3 inhibitors with DLI or combining HMA with venetoclax or LEN. Finally, personalized treatment plans should be systematically formulated according to the epigenetics and immune response of AML patients, from induction therapy to maintenance treatment after allo-HSCT. However, because of the numerous and complex complications that may be encountered, clinical studies involving new drugs for de novo or R/R AML patients often exclude patients receiving allo-HSCT.

At present, more and more AML patients who have relapsed after allo-HSCT benefit from novel targeted agents. Clinicians must abandon the notion that anti-tumor immune effects induced by DLI or second transplantation are the only way to cure relapse after allo-HSCT, just as allo-HSCT is the definitive treatment for high-risk AML. For more individualized and systematic treatment based on the epigenetics and immunophenotype of AML patients, it should be implemented from induction chemotherapy to maintenance therapy after allo-HSCT. Scientists and clinicians must conduct more clinical trials to test novel agents earlier in allo-HSCT recipients to ensure how they can be successfully applied to improve patient outcomes.

This work was supported by the National Natural Science Foundation of China 

The authors have no conflicts of interest to declare. Figure 1 Summary of novel agents that have been used to prevent or treat relapse after allo-HSCT. Salvage; salvage therapy for patients with hematological relapse; Maintenance, preventive therapy for high-risk patients without any sigh of underlying disease; Preemptive, preemptive therapy for patients with minimal residual disease; Promising agents, the agents in clinical trial; * , engineering NK or T cells are introduced in Table 1 .

Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantation

Outcome of 93 patients with relapse or progression following allogeneic hematopoietic cell transplantation

Relapse patterns and treatment strategies in patients receiving allogeneic hematopoietic stem cell transplantation for myeloid malignancies

Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT

Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation

Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia

Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study

Leukemia relapse following unmanipulated haploidentical transplantation: a risk factor analysis on behalf of the ALWP of the EBMT

Mechanisms of immune escape after allogeneic hematopoietic cell transplantation

Immune escape of relapsed AML cells after allogeneic transplantation

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT

Reversal of T cell exhaustion by the first donor lymphocyte infusion is associated with the persistently effective antileukemic responses in patients with relapsed AML after allo-HSCT

Killer cell immunoglobulin-like receptor ligand mismatching and outcome after haploidentical transplantation with post-transplant cyclophosphamide

Donor and host coexpressing KIR ligands promote NK education after allogeneic hematopoietic stem cell transplantation

HLA-C-dependent prevention of leukemia relapse by donor activating KIR2DS1

Influence of differently licensed KIR2DL1-positive natural killer cells in transplant recipients with acute leukemia: a Japanese national registry study

KIR B donors improve the outcome for AML patients given reduced intensity conditioning and unrelated donor transplantation

New targeted agents in acute myeloid leukemia: new hope on the rise

Recent developments in topoisomerase-targeted cancer chemotherapy

PRMT1-mediated FLT3 arginine methylation promotes maintenance of FLT3-ITD + acute myeloid leukemia

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

Sorafenib improves survival of FLT3-mutated acute myeloid leukemia in relapse after allogeneic stem cell transplantation: a report of the EBMT Acute Leukemia Working Party

Sorafenib therapy is associated with improved outcomes for FMS-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia relapsing after allogeneic hematopoietic stem cell transplantation

A prospective study of peritransplant sorafenib for patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic transplantation

Impact of FLT3-ITD allele ratio and ITD length on therapeutic outcome in cytogenetically normal AML patients without NPM1 mutation

Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival

Allogeneic stem cell transplantation for FLT3-mutated acute myeloid leukemia: in vivo T-cell depletion and posttransplant sorafenib maintenance improve survival. a retrospective acute leukemia working party-European society for blood and marrow transplant study

Sorafenib as maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre sormain trial

Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia

Haematopoietic cell transplantation with and without sorafenib maintenance for patients with FLT3-ITD acute myeloid leukaemia in first complete remission

Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation

Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant

Phase 1 study of quizartinib in combination with induction and consolidation chemotherapy in patients with newly diagnosed acute myeloid leukemia

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

Phase 2b study of 2 dosing regimens of quizartinib monotherapy in FLT3-ITD-mutated, relapsed or refractory AML

Clinical profile of gilteritinib in Japanese patients with relapsed/refractory acute myeloid leukemia: an open-label phase 1 study

Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms

FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions

Targeting BCL2 with venetoclax is a promising therapeutic strategy for "double-proteinexpression" lymphoma with MYC and BCL2 rearrangements

Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia

Venetoclax with decitabine or azacitidine for AML

Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia

Venetolax with azacitidine drains fuel from AML stem cells

Venetoclax combination therapy in relapsed/refractory acute myeloid leukemia: a single institution experience

Venetoclax and low-dose cytarabine induced complete remission in a patient with high-risk acute myeloid leukemia: a case report

How I treat acute myeloid leukemia in the era of new drugs

Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response

Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib

Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Differentiation syndrome associated with enasidenib, a selective inhibitor of mutant isocitrate dehydrogenase 2: analysis of a phase 1/2 study

Targeting hedgehog (Hh) pathway for the acute myeloid leukemia treatment

Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: phase 2 study results

Phase Ib study of glasdegib, a hedgehog pathway inhibitor, in combination with standard chemotherapy in patients with AML or high-risk MDS

Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome

Immunotherapeutic concepts to target acute myeloid leukemia: focusing on the role of monoclonal antibodies, hypomethylating agents and the leukemic microenvironment

Treatment of acute myeloid leukemia or myelodysplastic syndrome relapse after allogeneic stem cell transplantation with azacitidine and donor lymphocyte infusions-a retrospective multicenter analysis from the German Cooperative Transplant Study Group

Low-dose azacitidine with DNMT1 level monitoring to treat post-transplantation acute myelogenous leukemia or myelodysplastic syndrome relapse

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

Chemotherapy versus hypomethylating agents for the treatment of relapsed acute myeloid leukemia and myelodysplastic syndrome after allogeneic stem cell transplant

Factors determining responses to azacitidine in patients with myelodysplastic syndromes and acute myeloid leukemia with early post-transplantation relapse: a prospective trial

Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

Combination lenalidomide and azacitidine: a novel salvage therapy in patients who relapse after allogeneic stem-cell transplantation for acute myeloid leukemia

Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre

Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA trial

Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT

Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome

CC-486 maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes

Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with 30% blasts

Phase I/II study of the deacetylase inhibitor panobinostat after allogeneic stem cell transplantation in patients with high-risk MDS or AML (PANOBEST trial)

Safety and efficacy of oral panobinostat plus chemotherapy in patients aged 65 years or younger with high-risk acute myeloid leukemia

Histone deacetylase inhibition with panobinostat combined with intensive induction chemotherapy in older patients with acute myeloid leukemia: phase I study results

The role of targeted therapy in the management of patients with AML

Therapeutic targeting of acute myeloid leukemia stem cells

A phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

Anti-CD44 antibodies inhibit both mTORC1 and mTORC2: a new rationale supporting CD44-induced AML differentiation therapy

Phase I clinical study of RG7356, an anti-CD44 humanized antibody, in patients with acute myeloid leukemia

Characterization of CD33/CD3 tetravalent bispecific tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia

Gemtuzumab ozogamicin in acute myeloid leukemia

Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials

A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome

Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia: a report from the Children's Oncology Group

Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: final results and long term outcome of a phase II multicenter clinical trial

Gemtuzumab ozogamicin versus best supportive care in older patients with newly diagnosed acute myeloid leukemia unsuitable for intensive chemotherapy: results of the randomized phase III EORTC-GIMEMA AML-19 trial

Midostaurin, enasidenib, CPX-351, gemtuzumab ozogamicin, and venetoclax bring new hope to AML

Defining the dose of gemtuzumab ozogamicin in combination with induction chemotherapy in acute myeloid leukemia: a comparison of 3 mg/m 2 with 6 mg/m 2 in the NCRI AML17 Trial

CD33 expression and its association with gemtuzumab ozogamicin response: results from the randomized phase III Children's Oncology Group trial AAML0531

Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia

CD33 splicing polymorphism determines gemtuzumab ozogamicin response in de novo acute myeloid leukemia: report from randomized phase III Children's Oncology Group trial AAML0531

Salvage therapy with ARA-C and gemtuzumab ozogamicin in AML patients relapsing after stem cell transplantation

A phase I study of reduced-intensity conditioning and allogeneic stem cell transplantation followed by dose escalation of targeted consolidation immunotherapy with gemtuzumab ozogamicin in children and adolescents with CD33 + acute myeloid leukemia

A phase 1 trial of vadastuximab talirine as monotherapy in patients with CD33-positive acute myeloid leukemia

A phase 1 trial of vadastuximab talirine combined with hypomethylating agents in patients with CD33-positive AML

WT1 vaccination in AML and MDS: a pilot trial with synthetic analog peptides

T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant

Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia

post-transplantation relapse

Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS

The CXCR4 inhibitor BL-8040 induces the apoptosis of AML blasts by downregulating ERK, BCL-2, MCL-1 and cyclin-D1 via altered miR-15a/16-1 expression

Dual targeting of acute leukemia and supporting niche by CXCR4-directed theranostics

A novel CXCR4

PF-06747143) for the treatment of hematologic malignancies

Combination of the low anticoagulant heparin CX-01 with chemotherapy for the treatment of acute myeloid leukemia

of safety and tolerability

Targeting of folate receptor beta on acute myeloid leukemia blasts with chimeric antigen receptor-expressing T cells

High-affinity FRbeta-specific CAR T cells eradicate AML and normal myeloid lineage without HSC toxicity

CAR-T cells

Phase I trial of autologous CAR T cells targeting NKG2D ligands in patients with AML/MDS and multiple myeloma

Cells for the therapy of acute myeloid leukemia

CAR T-cells targeting FLT3 have potent activity against FLT3-ITD + AML and act synergistically with the FLT3-inhibitor crenolanib

Targeting FLT3 in acute myeloid leukemia using ligand-based chimeric antigen receptor-engineered T cells

Compound CAR T-cells as a double-pronged approach for treating acute myeloid leukemia

Bi-specific and split CAR T cells targeting CD13 and TIM3 eradicate acute myeloid leukemia

Genetic myeloid leukemia

Gene-edited stem cells enable CD33-directed immune therapy for myeloid malignancies

Loss of mismatched HLA in leukemia after stem-cell transplantation

A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT

Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aGvHD

Reversal of low donor chimerism after hematopoietic cell transplantation using pentostatin and donor lymphocyte infusion: a prospective phase II multicenter trial

Intentional donor lymphocyte-induced limited acute

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation

KIR3DL1/HLA-B subtypes govern acute myelogenous leukemia relapse after hematopoietic cell transplantation

Restoring T cell homeostasis after allogeneic stem cell transplantation: principal limitations and future challenges

Dynamics of expression of programmed cell death protein-1 (PD-1) on T cells after allogeneic hematopoietic stem cell transplantation

Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation

Ipilimumab for patients with relapse after allogeneic transplantation

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation

A phase I study of CD25/regulatory T-cell-depleted donor lymphocyte infusion for relapse after allogeneic stem cell transplantation

Infusion of donor-derived CD8 + memory T cells for relapse following allogeneic hematopoietic cell transplantation

CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia

The HLA-B-21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia

IL-15/IL-15Ralpha/CD80-expressing AML cell vaccines eradicate minimal residual disease in leukemic mice

First-in-human phase 1 clinical study of the IL-15

superagonist complex ALT-803 to treat relapse after transplantation

Cytogenetic evolution in myeloid neoplasms at relapse after allogeneic hematopoietic cell transplantation: association with previous chemotherapy and effect on survival

Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

A Menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia

Emerging epigenetic therapeutic targets in acute myeloid leukemia

Functional diversity of inhibitors tackling the differentiation blockage of MLL-rearranged leukemia

PRMT5 methylome profiling uncovers a direct link to splicing regulation in acute myeloid leukemia

Targeting nuclear beta-catenin as therapy for post-myeloproliferative neoplasm secondary AML

BETP degradation simultaneously targets acute myelogenous leukemia stem cells and the microenvironment

RUNX1-targeted therapy for AML expressing somatic or germline mutation in RUNX1

AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia

Effect of sorafenib on the outcomes of patients with FLT3-ITD acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation

Complete date, actual or estimated study completion date; Salvage, salvage therapy for patients with hematological relapse

Maintenance, preventive therapy for high-risk patients without any sigh of underlying disease

Preemptive, preemptive therapy for patients with minimal residual disease; Mono, monotherapy; +/−, the clinical trial has two arms, monotherapy or in combination with other regimens

DLI, donor lymphocyte infusion

APR-246, agent targeted TP53; 2 nd HSCT, the second allo-HSCT; CC-486

F16IL2, F16 antibody fused to human IL-2

WT1-sensitized T, WT1-sensitized allogeneic T-lymphocytes

CTL, donor CD8+cytotoxic T lymphocyte clones specific for WT1

interleukin-6 receptor antagonist; FLU, fludarabine; Ara-C, cytarabine; CTX, Cyclophosphamide; iNKT, invariant NKT cells

cytokine-induced memory-like (CIML) natural killer cell

CIK, cytokine induced killer cells

ALT-803 or N-803